Assessment of vitamin D status - a changing landscape.

摘要: In recent years it has been shown that vitamin D deficiency is associated with an increased incidence as well the progression of a broad range diseases including osteoporosis, rickets, cardiovascular disease, autoimmune multiple sclerosis and cancer. Consequently, requests for assessment status have dramatically. Despite significant progress in analysis metabolites expansion our pathophysiological knowledge D, remains challenging partially unresolved issue. Current guidelines from scientific bodies recommend measurement 25-hydroxy (25-OHD) blood preferred test. However, growing evidence indicates limitations this test, analytical aspects interpretation results. addition, relationships between 25-OHD various clinical indices, such bone mineral density fracture risk, are rather weak not consistent across races. Recent studies systematically investigated new markers metabolite ratio (VMR) (ratio 24,25-dihydroxy D), bioavailable [25-OHD bound to binding protein (DBP)], free [circulating neither DBP nor albumin (ALB)]. These parameters may potentially change how we will assess future. Although these biomarkers expanded about metabolism, issues regarding their results prevent use daily practice. It can be expected some overcome near future so they considered routine (at least specialized centers). genetic revealed several polymorphisms key proteins metabolism affect circulating concentrations metabolites. The affected include DBP, 7-dehydrocholesterol synthase receptor (VDR). Here aim review existing biochemistry, physiology D. We also provide overview current emerging status, particular attention methodological usefulness